On a Mission to Standardize Proteomics Workflows

Key Takeaways

• Evosep launches Proteomics ecosystem unifying sample prep to LC‑MS analysis
• Lupo system reduces manual steps, delivering low‑variance, AI‑ready data
• Evokit kits standardize preparation, targeting $10 per sample cost
• Standardized workflow aims to accelerate drug target discovery and biomarker validation
• Consistent data supports NAMs, MRD monitoring, and multi‑site pharmaceutical studies

Pulse Analysis

Proteomics has become a cornerstone of modern drug discovery, yet the field has long been hampered by fragmented workflows and manual sample‑preparation steps that introduce variability. As pharmaceutical R&D leans increasingly on big‑data analytics and artificial intelligence, the need for reproducible, high‑throughput data pipelines has intensified. Industry analysts estimate that the global proteomics market will exceed $30 billion by 2030, driven largely by demand for reliable biomarkers and mechanistic insights across both preclinical and clinical stages.

Evosep’s new Proteomics ecosystem tackles these challenges head‑on by coupling its Evokit sample‑prep kits with the Lupo automated preparation platform and seamless integration to Evosep One and Eno LC‑MS systems. The standardized workflow promises low‑variance outputs at roughly $10 per sample, a price point that makes large‑scale studies financially viable. Built‑in quality controls, consumable tracking, and AI‑ready data formats further reduce the time scientists spend on data cleaning, allowing them to focus on hypothesis generation and model training.

The broader impact extends beyond cost savings. Consistent, interoperable data enables pharmaceutical teams to run multi‑site studies with confidence, accelerate New Approach Methodologies that replace animal testing, and monitor minimal residual disease with greater sensitivity. As AI algorithms mature, having a reliable proteomic foundation will be essential for predictive modeling, patient stratification, and rapid decision‑making in drug pipelines. Evosep’s move signals a shift toward industrial‑scale proteomics, positioning the company as a key enabler of the next wave of data‑driven therapeutics.